Puretech Health Plc ADR (PRTC)

$16.95 -0.81 (-4.56%)
Market Cap 412.60M
Revenue (ttm) 4.83M
Net Income (ttm) 27.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 575.16%
Debt to Equity Ratio 0.00
Volume 7,000
Avg Vol 4,196
Day's Range N/A - N/A
Shares Out 24.34M
Stochastic %K 0%
Beta 1.07
Analysts Strong Buy
Price Target $46.00

Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 482 2333
Fax: 617 482 3337
Address:
6 Tide Street, Suite 400, Boston, United States
ChadTrades3
ChadTrades3 Apr. 22 at 11:28 AM
$PRTC 122 watchers only
0 · Reply
ChadTrades3
ChadTrades3 Apr. 22 at 11:28 AM
$PRTC where is everyone?
0 · Reply
BioTuesdays
BioTuesdays Apr. 2 at 1:06 PM
$PRTC has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo (SPT-320 or Glyph Agomelatine) in generalized anxiety disorder (GAD). https://biotuesdays.com/2026/04/02/puretechs-seaport-reports-positive-data-from-trial-of-glyphago-in-gad/
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 2 at 12:21 PM
$PRTC (+3.6% pre) PureTech publishes phase 2b trial results for lung fibrosis drug https://ooc.bz/l/97914
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 9:42 PM
$PRTC RSI: 47.23, MACD: -0.2690 Vol: 0.45, MA20: 17.36, MA50: 17.75 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 8:06 PM
$PRTC RSI: 29.17, MACD: -0.1642 Vol: 0.61, MA20: 17.95, MA50: 17.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 27 at 10:31 AM
$PRTC trading at $19.06, with highs at $19.84 and lows at $13.49. Recent volume averaging 4,329, with last session at 1,900.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 8:38 PM
$PRTC RSI: 88.86, MACD: 0.4708 Vol: 0.80, MA20: 17.27, MA50: 16.89 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 10:45 PM
$PRTC Current Stock Price: $16.72
0 · Reply
ResonanceRadius
ResonanceRadius Dec. 25 at 5:22 PM
$PRTC This ticker is entering a stage where execution quality will overshadow headline narratives. Cost discipline must coexist with targeted investment. Smart capital allocation could unlock optionality not yet reflected. The thesis improves only as operational proof accumulates.
0 · Reply
Latest News on PRTC
Positive Phase 1b Results for PureTech Health (PRTC)

2026-04-22T12:53:18.000Z - 3 days ago

Positive Phase 1b Results for PureTech Health (PRTC)

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

Wed, 22 Apr 2026 07:00:00 -0400 - 3 days ago

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

PureTech Health: Notice of Results

Apr 13, 2026, 2:05 AM EDT - 12 days ago

PureTech Health: Notice of Results

PRTC

PureTech Health (PRTC) Advances Deupirfenidone for Pulmonary Fibrosis Treatment

2026-04-02T13:52:03.000Z - 23 days ago

PureTech Health (PRTC) Advances Deupirfenidone for Pulmonary Fibrosis Treatment

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

Apr 2, 2026, 8:19 AM EDT - 23 days ago

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

PRTC

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

Mar 25, 2026, 2:04 PM EDT - 4 weeks ago

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

PRTC

PureTech to Present at the Leerink Partners Global Healthcare Conference

Feb 25, 2026, 2:00 AM EST - 2 months ago

PureTech to Present at the Leerink Partners Global Healthcare Conference

PRTC

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Feb 19, 2026, 12:36 PM EST - 2 months ago

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

PRTC

PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 3 months ago

PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

PRTC

PureTech Appoints Robert Lyne as Chief Executive Officer

Dec 18, 2025, 2:00 AM EST - 4 months ago

PureTech Appoints Robert Lyne as Chief Executive Officer

PRTC

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Dec 8, 2025, 2:00 AM EST - 4 months ago

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

PRTC

PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Dec 5, 2025, 1:00 PM EST - 5 months ago

PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

PRTC

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Oct 22, 2025, 2:00 AM EDT - 6 months ago

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

PRTC

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

Sep 29, 2025, 2:00 AM EDT - 7 months ago

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

PRTC

PureTech Health plc – Half-Year Report

Aug 28, 2025, 2:00 AM EDT - 8 months ago

PureTech Health plc – Half-Year Report

PRTC

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

Aug 21, 2025, 7:00 AM EDT - 8 months ago

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

PRTC

PureTech Health: Notice of Half-Yearly Results

Aug 18, 2025, 2:00 AM EDT - 8 months ago

PureTech Health: Notice of Half-Yearly Results

PRTC

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

Aug 13, 2025, 12:16 PM EDT - 9 months ago

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

PRTC

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

Aug 12, 2025, 7:00 AM EDT - 9 months ago

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

PRTC

PureTech Announces Leadership Transition

Jul 16, 2025, 2:00 AM EDT - 10 months ago

PureTech Announces Leadership Transition

PRTC

PureTech Announces Board Change

Jul 8, 2025, 12:45 PM EDT - 10 months ago

PureTech Announces Board Change

PRTC

PureTech Health: Results of Annual General Meeting

Jun 16, 2025, 12:59 PM EDT - 11 months ago

PureTech Health: Results of Annual General Meeting

PRTC

PureTech to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 7:00 AM EDT - 1 year ago

PureTech to Present at the Jefferies Global Healthcare Conference

PRTC

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

May 9, 2025, 7:00 AM EDT - 1 year ago

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

PRTC

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

May 1, 2025, 7:00 AM EDT - 1 year ago

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

PRTC

PureTech Announces Annual Results for Year Ended December 31, 2024

Apr 30, 2025, 2:00 AM EDT - 1 year ago

PureTech Announces Annual Results for Year Ended December 31, 2024

PRTC

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

Apr 9, 2025, 2:00 AM EDT - 1 year ago

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

PRTC

PureTech Health plc Statement Regarding Press Speculation

Apr 7, 2025, 12:16 PM EDT - 1 year ago

PureTech Health plc Statement Regarding Press Speculation

PRTC

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Mar 11, 2025, 7:05 AM EDT - 1 year ago

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

PRTC

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

Feb 12, 2025, 7:05 AM EST - 1 year ago

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

PRTC

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

Jan 27, 2025, 2:00 AM EST - 1 year ago

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PRTC

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Jan 9, 2025, 7:00 AM EST - 1 year ago

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PRTC

PureTech Appoints UBS as UK Corporate Broker

Jan 6, 2025, 2:00 AM EST - 1 year ago

PureTech Appoints UBS as UK Corporate Broker

PRTC

PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

Dec 16, 2024, 2:00 AM EST - 1 year ago

PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PRTC

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Dec 11, 2024, 7:05 AM EST - 1 year ago

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PRTC

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

Dec 9, 2024, 2:00 AM EST - 1 year ago

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PRTC

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

Nov 20, 2024, 7:05 AM EST - 1 year ago

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

PRTC

PureTech to Present at CHEST 2024 Annual Meeting

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PureTech to Present at CHEST 2024 Annual Meeting

PRTC

PureTech Health plc – Half-Year Report

Aug 28, 2024, 2:01 AM EDT - 1 year ago

PureTech Health plc – Half-Year Report

PRTC

PureTech Health: Results of the Tender Offer

Jun 24, 2024, 2:00 AM EDT - 1 year ago

PureTech Health: Results of the Tender Offer

PRTC

PureTech Announces Change of Board Role

Jun 20, 2024, 2:00 AM EDT - 2 years ago

PureTech Announces Change of Board Role

PRTC

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team

Jun 18, 2024, 7:05 AM EDT - 2 years ago

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team

PRTC

PureTech Health: Result of General Meeting

Jun 6, 2024, 12:38 PM EDT - 2 years ago

PureTech Health: Result of General Meeting

PRTC

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company

May 29, 2024, 8:09 AM EDT - 2 years ago

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company

AKLI PRTC

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

May 21, 2024, 7:05 AM EDT - 2 years ago

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

PRTC

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

May 20, 2024, 2:00 AM EDT - 2 years ago

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

PRTC

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

May 9, 2024, 7:05 AM EDT - 2 years ago

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

PRTC

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

May 7, 2024, 7:05 AM EDT - 2 years ago

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

PRTC

PureTech Announces Annual Results for Year Ended December 31, 2023

Apr 25, 2024, 5:22 AM EDT - 2 years ago

PureTech Announces Annual Results for Year Ended December 31, 2023

PRTC

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

Apr 16, 2024, 7:00 AM EDT - 2 years ago

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

PRTC

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

Apr 11, 2024, 7:00 AM EDT - 2 years ago

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Apr 9, 2024, 2:00 AM EDT - 2 years ago

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

ChadTrades3
ChadTrades3 Apr. 22 at 11:28 AM
$PRTC 122 watchers only
0 · Reply
ChadTrades3
ChadTrades3 Apr. 22 at 11:28 AM
$PRTC where is everyone?
0 · Reply
BioTuesdays
BioTuesdays Apr. 2 at 1:06 PM
$PRTC has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo (SPT-320 or Glyph Agomelatine) in generalized anxiety disorder (GAD). https://biotuesdays.com/2026/04/02/puretechs-seaport-reports-positive-data-from-trial-of-glyphago-in-gad/
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 2 at 12:21 PM
$PRTC (+3.6% pre) PureTech publishes phase 2b trial results for lung fibrosis drug https://ooc.bz/l/97914
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 9:42 PM
$PRTC RSI: 47.23, MACD: -0.2690 Vol: 0.45, MA20: 17.36, MA50: 17.75 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 8:06 PM
$PRTC RSI: 29.17, MACD: -0.1642 Vol: 0.61, MA20: 17.95, MA50: 17.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 27 at 10:31 AM
$PRTC trading at $19.06, with highs at $19.84 and lows at $13.49. Recent volume averaging 4,329, with last session at 1,900.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 8:38 PM
$PRTC RSI: 88.86, MACD: 0.4708 Vol: 0.80, MA20: 17.27, MA50: 16.89 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 10:45 PM
$PRTC Current Stock Price: $16.72
0 · Reply
ResonanceRadius
ResonanceRadius Dec. 25 at 5:22 PM
$PRTC This ticker is entering a stage where execution quality will overshadow headline narratives. Cost discipline must coexist with targeted investment. Smart capital allocation could unlock optionality not yet reflected. The thesis improves only as operational proof accumulates.
0 · Reply
BioTuesdays
BioTuesdays Dec. 18 at 4:43 PM
$PRTC has announced the appointment of Robert Lyne as chief executive officer (CEO), and member of the board of directors, effective immediately https://biotuesdays.com/2025/12/18/puretech-appoints-robert-lyne-as-ceo/
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 11 at 6:21 PM
$PRTC
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 8 at 1:47 PM
$PRTC (-8.1% pre) PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis https://ooc.bz/l/86630
0 · Reply
briefingcom
briefingcom Dec. 8 at 1:08 PM
$PRTC (-5.1%): PureTech Health advances deupirfenidone toward pivotal Phase 3 in idiopathic pulmonary fibrosis https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251208051736PRTC&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 5 at 1:11 PM
$PRTC Current Stock Price: $17.10 No options data available.
0 · Reply
nikitatrades
nikitatrades Oct. 5 at 1:48 PM
$PRTC's hub-and-spoke model spins out mature assets (Seaport, Gallop, Celea) to attract external capital, reducing parent R&D burn while retaining equity & royalties. This extends cash runway past 2028 and shifts funding risk to VCs. 🧬 #BiotechStrategy
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 7:20 PM
$PRTC Great piece that accurately captures PRTC's current position. So if you want to refresh your understanding of PRTC or learn about PRTC for the first time, this is essential reading. https://beyondspx.com/quote/PRTC/analysis/puretech-health-unlocking-value-through-de-risked-innovation-and-strategic-spin-outs-prtc
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 11 at 11:13 AM
$PRTC Puretech Founded Entity Seaport Therapeutics Doses First Participant In Phase 1 Study Of Glyphago SPT-320 Oral Prodrug Of Agomelatine For Generalized Anxiety Disorder
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 14 at 10:23 AM
WATCHLIST AUG 14 2025 $SRFM Surf Air Mobility And Electra Showcase Ultra Short Takeoff/Landing Hybrid-Electric Aircraft, Paving Way For New Direct Aviation Routes By 2029 $PRTC PureTech Health's Founded Entity, Vedanta Biosciences, Says Its Candidate VE202 Did Not Meet Primary Endpoint In Phase 2 COLLECTiVE202 Study For Treatment Of UC Patients $FOSL Fossil Group Announces Refinancing Of Its Debt Through A New $150M Asset-based Credit Facility With Ares Management $RIG Barclays Maintains Overweight on Transocean, Raises Price Target to $4 $BIVI BioVie To Present Poster Highlighting Design And Enrichment Strategy Of Its Ongoing Phase 2 ADDRESS-LC Trial At Keystone Symposia
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 26 at 12:23 PM
$VOR (+110.9% pre) $PRTC PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement https://ooc.bz/l/68777
0 · Reply
DonCorleone77
DonCorleone77 Jun. 26 at 10:17 AM
$PRTC $VOR PureTech Health founded entity Vor Bio enters license agreement with RemeGen PureTech Health (PRTC) noted that its founded entity, Vor Bio (VOR) and RemeGen announced entry into an exclusive license agreement granting Vor Bio global rights to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125M consisting of an upfront payment of $45M as well as $80M of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4B, in addition to tiered royalties.
0 · Reply